Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
| Revenue (Most Recent Fiscal Year) | $28.75B |
| Net Income (Most Recent Fiscal Year) | $480.00M |
| PE Ratio (Current Year Earnings Estimate) | 13.11 |
| PE Ratio (Trailing 12 Months) | 13.40 |
| PEG Ratio (Long Term Growth Estimate) | 0.67 |
| Price to Sales Ratio (Trailing 12 Months) | 4.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 15.09 |
| Pre-Tax Margin (Trailing 12 Months) | 23.75% |
| Net Margin (Trailing 12 Months) | 20.76% |
| Return on Equity (Trailing 12 Months) | 51.93% |
| Return on Assets (Trailing 12 Months) | 17.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.00 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.36 |
| Inventory Turnover (Trailing 12 Months) | 2.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.44 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.81 |
| Earnings per Share (Most Recent Fiscal Year) | $4.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $4.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 1.25B |
| Free Float | 1.24B |
| Market Capitalization | $129.10B |
| Average Volume (Last 20 Days) | 9.23M |
| Beta (Past 60 Months) | 0.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.27% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.67% |
| Annual Dividend (Based on Last Quarter) | $3.16 |
| Dividend Yield (Based on Last Quarter) | 3.05% |